Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Q3 earnings and clinical updates put Recursion Pharmaceuticals (RXRX) in focus Recursion Pharmaceuticals (RXRX) just ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive Phase 2 data for oral MEK1/2 inhibitor REC-4881 in familial ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has counted Nvidia as an investor since 2023 when Jensen Huang's company invested ...

Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.

Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...

Recursion Pharmaceuticals, Inc. ( RXRX ), a clinical-stage company pioneering AI-enabled drug discovery and development, reported third-quarter results ended September 30, 2026, reflecting a narrower ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Monday reported a loss of $119 million ...

A $10 million Sanofi milestone drove revenue 258% higher year over year, beating expectations and showing the AI platform ...

Quarter includes a $10.0 million Sanofi milestone payment recognized in collaboration revenue; prior-year quarter included $22.8 million of in-process R&D costs for REC-102 that did not recur. Revenue ...

Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, ...

Recursion Pharmaceuticals, Inc. Announces Sanofi Options Potential First-In-Class Immunology Development Candidate From Their Collaboration CI Oct. 15 Recursion Prices $200 Million Stock Offering, ...